Obermatt
See Similar Stocks →

IDEAYA Biosciences

NSQ:IDYA · US45166A1025
BiotechnologySmall

360

18
Profit price82
Owner Earnings Yield1
Dividend Yield1
Price/Sales45
Price/Book41
Return on Capital65
Cash Return on Capital63
Return on Equity67
EBIT Margin24
Gross Profitability31
Accruals69
Owner Earnings Margin52
Sales growth7
Profit growth8
Reinvestment58
Price momentum46
Debt load51
Refinancing45
Debt Payback1
Liquidity5
Analyst ratings34
Opinion Changes50
Price Target Upside57
Market mood73
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

IDEAYA Biosciences doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2015
Employees229
Websiteideayabio.com
ISINUS45166A1025
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsMachine LearningImmunologyOphthalmologyOncologyGeneticsArtificial IntelligenceApp DiscoveryBiotechnologyHealth Care

Description

IDEAYA Biosciences, Inc. operates as a precision medicine oncology company. The company is committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Pipeline The company's curr…

Analysis

Middle-of-the-road

IDEAYA Biosciences, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
7
2026

All-time high

30

Mar 2026

All-time low

7

Jun 2026

Average rank

19

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
45
—
—
—
Price/Earnings
57
—
—
—
Price/Book
41
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
12
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare IDEAYA Biosciences with its peers
Relay Therapeutics
NMQ:RLAY
23
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
PMV Pharmaceuticals
NSQ:PMVP
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Incyte
NSQ:INCY
95
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Dyne Therapeutics
NSQ:DYN
34
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zentalis Pharmaceuticals
NMQ:ZNTL
12
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Assembly Biosciences
NSQ:ASMB
33
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →